A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Corcept Therapeutics
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
Immatics US, Inc.
Parabilis Medicines, Inc.
Hospital Universitari de Bellvitge
Revolution Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Conjupro Biotherapeutics, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Epsilogen Ltd
AbbVie
Conjupro Biotherapeutics, Inc.
University Hospital, Brest
Imperial College London
Colorado State University
ZIWIG
Memorial Sloan Kettering Cancer Center
Avera McKennan Hospital & University Health Center
AIDS Malignancy Consortium
Unidade Local de Saúde São João
Eisai Inc.
AstraZeneca
GlaxoSmithKline
Assistance Publique - Hôpitaux de Paris
Rutgers, The State University of New Jersey
GlaxoSmithKline
Rondo Therapeutics